Assembly Biosciences (NASDAQ:ASMB) Upgraded at Zacks Research

Assembly Biosciences (NASDAQ:ASMB) was upgraded by stock analysts at Zacks Research to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

Separately, HC Wainwright assumed coverage on shares of Assembly Biosciences in a research report on Monday. They issued a “buy” rating and a $50.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $38.67.

Assembly Biosciences Stock Performance

NASDAQ ASMB opened at $26.15 on Tuesday. The stock has a market cap of $200.57 million, a price-to-earnings ratio of -4.69 and a beta of 0.64. The business has a 50 day simple moving average of $19.40 and a 200 day simple moving average of $14.58. Assembly Biosciences has a 52-week low of $7.75 and a 52-week high of $26.25.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.73) by $0.40. Assembly Biosciences had a negative net margin of 117.20% and a negative return on equity of 149.01%. The firm had revenue of $9.63 million for the quarter, compared to analyst estimates of $5.30 million. On average, analysts predict that Assembly Biosciences will post -6.87 EPS for the current year.

Institutional Trading of Assembly Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. acquired a new position in Assembly Biosciences during the first quarter valued at approximately $113,000. Palumbo Wealth Management LLC increased its position in shares of Assembly Biosciences by 57.4% during the 1st quarter. Palumbo Wealth Management LLC now owns 17,986 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 6,559 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Assembly Biosciences by 225.6% during the 4th quarter. JPMorgan Chase & Co. now owns 11,427 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 7,918 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 6,823 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Assembly Biosciences by 16.5% in the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 2,098 shares during the last quarter. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.